Compare Five9 Inc (FIVN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Neurocrine Biosciences Inc — how do they compare? Five9 Inc trades at $31.12 (market cap $2.44B), while Neurocrine Biosciences Inc trades at $156.95 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.7× Five9 Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | NBIX | |
|---|---|---|
Market Cap | $2.44B | $16.46B |
Sector | Technology | Health |
52-Week High | $34.48 | $185.50 |
52-Week Low | $13.61 | $123.10 |
Enterprise Value | $2.59B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIVN trades at $31.37, down 9.02% in the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million. Recent management appointments and AI-driven subscription growth provide operational tailwinds.
Outlook is positive given earnings beats and analyst consensus, but risks include high valuation multiples and negative cash flow trends. The stock offers growth potential but requires monitoring of debt levels and competitive pressures in the CX software space.
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
